Literature DB >> 7927950

EGF modulation of the ras-related rhoB gene expression in human breast-cancer cell lines.

P de Cremoux1, C Gauville, V Closson, G Linares, F Calvo, A Tavitian, B Olofsson.   

Abstract

The mRNA levels of the ras-related human rhoA, rhoB and rhoC genes were studied in human breast-cancer cell lines (HBCal), and in normal and immortalized mammary epithelial cells (HMEC) by Northern blot analysis and in situ hybridization. In contrast to the ubiquitous rhoA and rhoC gene expression, dramatic variations in the mRNA level of the rhoB gene were evidenced. The rhoB mRNA level appeared to be inversely correlated to the amounts of the epidermal-growth-factor(EGF) receptors in these cells. The rhoB transcripts were detected at high levels in ZR75-1, MCF7, HSL 53, HSL 59, HSL 90, T47D and SKBR3 HBCal, at hardly detectable levels in BT 20, MDA-MB 231 and H466B HBCal and at intermediate levels in normal and immortalized breast epithelial cells. Rapid and transient induction of the rhoB transcription was observed after EGF treatment in serum-deprived MDA-MB231, T47D and immortalized epithelial cells. In contrast, no modulation of rhoB expression by EGF could be objectified in the MCF7 and ZR75-1 cell lines. Yet a normal function of EGF receptors was evidenced, since the immediate early gene c-fos was rapidly induced, suggesting a constitutive expression of rhoB in these cell lines bypassing the regulation by EGF. In human mammary epithelial cells, rhoB mRNA is rapidly and transiently induced with EGF concentrations known to stimulate cell proliferation. This suggests that the rhoB product might be involved in a cascade that initiates or promotes cell proliferation, and plays an important role in EGF-stimulated growth of breast normal and cancer cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927950     DOI: 10.1002/ijc.2910590320

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Combined analysis of in situ hybridization, cell cycle and structural markers using reflectance and immunofluorescence confocal microscopy.

Authors:  G Linares-Cruz; G Millot; P De Cremoux; J Vassy; B Olofsson; J P Rigaut; F Calvo
Journal:  Histochem J       Date:  1995-01

2.  RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA.

Authors:  Grant A Howe; Christina L Addison
Journal:  Vasc Cell       Date:  2012-02-08

3.  The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage.

Authors:  Melissa C Srougi; Keith Burridge
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

4.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.

Authors:  H Suwa; G Ohshio; T Imamura; G Watanabe; S Arii; M Imamura; S Narumiya; H Hiai; M Fukumoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.

Authors:  Philippe Cestac; Guillaume Sarrabayrouse; Claire Médale-Giamarchi; Philippe Rochaix; Patrick Balaguer; Gilles Favre; Jean-Charles Faye; Sophie Doisneau-Sixou
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

6.  The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.

Authors:  Olivier Calvayrac; Julien Mazières; Sarah Figarol; Claire Marty-Detraves; Isabelle Raymond-Letron; Emilie Bousquet; Magali Farella; Estelle Clermont-Taranchon; Julie Milia; Isabelle Rouquette; Nicolas Guibert; Amélie Lusque; Jacques Cadranel; Nathalie Mathiot; Ariel Savina; Anne Pradines; Gilles Favre
Journal:  EMBO Mol Med       Date:  2017-02       Impact factor: 12.137

7.  RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor.

Authors:  Claire Médale-Giamarchi; Isabelle Lajoie-Mazenc; Emilie Malissein; Elise Meunier; Bettina Couderc; Yann Bergé; Thomas Filleron; Laura Keller; Claudine Marty; Magali Lacroix-Triki; Florence Dalenc; Sophie F Doisneau-Sixou; Gilles Favre
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466

8.  Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion.

Authors:  Min Chen; Teresa Knifley; Thangaiah Subramanian; H Peter Spielmann; Kathleen L O'Connor
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.